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Background. In selected patients with peritoneal carcinomatosis (PC) originating from colorectal cancer (CRC) the high dosage of
oxaliplatin (460mg/m2) is recommended for hyperthermic intraperitoneal chemotherapy (HIPEC), which may be a health risk to
those administering the drug. The aim of this study was to determine the risk of platinum (Pt) exposure for the two main people
handlingandadministeringthecytotoxic agentduringHIPEC.Methods.Samplesofbloodand urinewere collected fromone male
surgeon and one female perfusionist during oxaliplatin-based HIPEC treatment with open abdomen coliseum technique on six
consecutive patients with PC from CRC. Results. All blood samples analysed were below the detection limit of < 0.05nmol/L Pt,
and the urine samples were all below the detection limit of < 0.03nmol/L Pt. Conclusions. There appears to be little or no risk of
Pt exposure during HIPEC when the recommended protective garment is used and the safety considerations are followed.
1.Introduction
Peritoneal carcinomatosis (PC) from colorectal cancer
(CRC) is often associated with poor prognosis [1–3]. How-
ever,growingevidenceindicatescytoreductivesurgery(CRS)
combined with hyperthermic intraperitoneal chemotherapy
(HIPEC)isaneﬀectivetreatmentforpatientsinthiscategory
[4–6].
Oxaliplatin is a third generation platinum (Pt) complex
used intravenously, at the dose of 85–100mg/m2 [7, 8], to
treat advanced CRC. With HIPEC, a higher oxaliplatin dose
of 460mg/m2 is recommended [9], and with this dosage, a
65%–75% overall survival rate of two years and an estimated
ﬁve-year survival rate of 40% are reported [5, 10].
The use of oxaliplatin in the HIPEC setting may be a
health risk for those administering the cytotoxic agent, as the
heated cytotoxic agents may vaporise and become inhaled
by health personnel [11]; thus, the guidelines should be
followed to minimise exposure [12]. Although insigniﬁcant
amounts of oxaliplatin are vaporised during HIPEC [13], the
occurrence of Pt in surgeons and perfusionists exposed to
oxaliplatin has not been investigated.
The aim of this study was to determine, through blood
and urine sampling, the risk of Pt exposure for the two
main people handling and administering the cytotoxic agent
during HIPEC.
2.MaterialandMethods
In 2008, six consecutive patients (4 men and 2 women,
mean age 54.2 years (range 43–65)) with PC from CRC,
with a mean peritoneal cancer index score 16.3 (range 7–
32), underwent CRS and oxaliplatin-based HIPEC treatment
at the University Hospital, Uppsala, Sweden. During these2 Journal of Oncology










Female/CRC with PC 48 158 1.47 600
Male/CRC with PC 96 178 2.14 960
Male/CRC with PC 87 185 2.11 960
Male/CRC with PC 82 173 1.96 890
Male/CRC with PC 80 170 1.91 870
Female/CRC with PC 72 164 1.78 380
CRC:C o l o r e c t a lc a n c e r ;PC: Peritoneal carcinomatosis; HIPEC: hyperthermic intraperitoneal chemotherapy.
treatments, blood and urine samples were taken from one
surgeon and one perfusionist to determine any presence of
Pt,andtheseanalysesarethebasisofthisreport.Theregional
ethics committees approved the study.
2.1. HIPEC. HIPEC was performed by the open abdomen
coliseum technique, as described earlier [14–16]. A thick
plastic sheet was thoroughly sutured around the skin edges
of the incision and a sterile tube system created a closed
circuit for the heated chemotherapy agent to circulate. A
smoke-evacuating device (Smoke Plume Evacuation System,
ERBEIES2,2.1m,Artnr2-20321-012,T¨ ubingen,Germany)
with a diameter of 22mm was connected to a suction
generator (ERBE IES 2, Type nr 10321-000, App nr C-2046,
Elektromedizin, T¨ ubingen, Germany) and placed on the
caudal part of the self-retaining retractor. The hose pointed
towards a minimal incision in the plastic sheet where the
surgeon could pass his arm and hand into the abdominal
cavity to distribute the heated oxaliplatin solution. As a
complement, on the opposite side of the smoke-evacuating
device, an evacuation device for the anaesthetic gas was
placed on the anaesthesia screen, also pointing towards the
incision in the plastic sheet.
The patients received a dose of 460-mg/m2 oxaliplatin
(Table 1) and a concomitant intravenous (iv) 5-ﬂuorouracil
(500mg/m2)p l u si vl e u c o v o r i n( 6 0 m g / m 2). The body
surface area determined the volume of the electrolyte-free
glucose (50mg/mL) carrier solution. The roller-pump was
set to a ﬂow of 2L/min, and the heat exchanger was set
to heat the in-ﬂowing oxaliplatin to 45–46◦C. The mean
temperature in the abdominal cavity during HIPEC was
42.2◦C (range 39.7–43.4◦C). The perfusion lasted for 30
minutes, as described by Elias [9]. The oxaliplatin was
evacuated directly after complete perfusion.
For HIPEC, the main two people compelled to stay in the
operating room are the surgeon, who is responsible for the
treatment and distributes the cytotoxic agent in the patient’s
abdomen by hand, and the perfusionist, who circulates the
chemotherapy via a heat exchanger with the help of a roller-
pump.ThroughouttheHIPEC,thesurgeon(sterile)isplaced
in the surgical ﬁeld, and the perfusionist (nonsterile) stands
approximately 1–1.5 meters from the surgical ﬁeld.
2.2. Protective Garment. The surgeon was dressed in a
protective barrier sterile garment, wearing a high power
ﬁltration mask (3M Health Care Respirator, 1883, EN
149:2001, FFP3, 3M Svenska AB, avd. H¨ alsovard, Sollentuna,
Sweden)andeyeprotection,asdescribedbyGonz´ alez-Bay´ on
et al. [14]. A double pair of latex gloves (Biogel Eclipse
Indicator, Ref 60775, M¨ olnlycke Healthcare, Gothenburg,
Sweden) was used together with an extra long latex glove
(WRP Dermagrip, Elbow Length Procedure Gloves, Reorder
#: D3985-15, Vienna, Austria) on the arm penetrating the
plastic sheet to circulate the cytotoxic agent. The perfusionist
wore a nonsterile protective garment, a high power ﬁltra-
tion mask, and nonsterile gloves specially made for toxic
agents(Lirtin—ExtraLong,100%Nitrile—NonLatex.Exam
gloves, Powder free. Art.no: 21-0247. SELFATRADE, Sp˚ anga,
Sweden).
2.3. Sampling. Samples of blood and urine were collected
from one male surgeon and one female perfusionist during
all six treatment occasions. Both surgeon and perfusionist
were in excellent health, and neither of them took any
medication at the time of the study. The surgeon was
179cm and weighed 70kg, the perfusionist was 172cm
and weighed 67kg. They had no history of liver- or
kidney problems/disease. Creatinine levels were 65µmol/L
(surgeon) and 66µmol/L (perfusionist).
On each of the six treatment occasions, three samples
of blood per person were drawn: one sample ﬁve minutes
before,onesample15minutesduringthe30-minuteHIPEC-
procedure,andthelastsample45minutesafterthetreatment
ended. Three urine samples per person and procedure were
collected: one just before HIPEC; one approximately two
hours after completed treatment; one 12–15 hours after
HIPEC. From each of the six procedures, twelve specimens
were collected around and during the 30-minute procedure.
Urine samples were collected in 50mL plastic bottles
and blood samples in 10mL heparin containing tubes. After
collection, the samples were stored at 4◦C, before being
sent by mail for analysis at ALS Scandinavia AB (Lule˚ a,
Sweden). Whole blood samples (1mL) were microwave-
digested (1200W 80%, ramp 10 minutes up to 180◦C, 180◦C
for50minutes)in1mL65% nitric acidinTeﬂonvessels.The
urine samples (0.5mL) were diluted with 8.5mL MilliporeJournal of Oncology 3
water and 1mL nitric acid before analysis. Platinum in
the prepared samples was measured by inductively coupled
plasma-sector ﬁeld mass spectrometry (ICP-SFMS): the
method was modiﬁed from EPA method 200.7 and 200.8
[17, 18]. The detection limit for Pt in blood was 0.05nmol/L
and for Pt in urine 0.01nmol/L.
3. Results
During this study, 18 samples of blood and 18 samples
of urine were collected per person (a total amount of 36
samples of blood and 36 samples of urine were analysed).
Analyses from blood samples taken ﬁve minutes before, 15
minutes during the 30-minute HIPEC-procedure, and 45
minutes after the treatment revealed no detectable levels of
Pt. Furthermore, analyses of urine samples taken just before
HIPEC, approximately two hours after completed treatment,
and 12–15 hours after HIPEC revealed no detectable levels of
Pt.
The 36 blood samples were all below the detection limit
of <0.05nmol/L, and the 36 urine samples were all below the
detection limit of <0.01µg/L.
4. Discussion
No detectable signs of Pt in the blood or urine of either
the surgeon, who was most at risk by being closest to the
cytotoxic agent, or the perfusionist during six 30-minute
HIPEC-perfusions of oxaliplatin were detected. This might
beduetothespeciﬁchighpowerﬁltrationmasksusedduring
HIPECandthattheopenabdomenwascoveredwithaplastic
sheet. As the surgeon was exposed to direct contact with
oxaliplatin while stirring by hand in the peritoneal cavity,
this could indicate the importance of wearing three layers of
gloves, where one must cover the arm to the elbow [14].
T h ea n a l y s i so fP tw a si nw h o l eb l o o d ,a sa b o u t4 0 %
of Pt is distributed in the red blood cells [19]. Urine
was sampled as renal elimination is the major excretion
pathway and about 50% of Pt is excreted in urine [20]. The
analytical technique used has an extremely low detection
limit (<0.05nmol/L), and despite optimal sampling, no Pt
wasdetected.Theoxaliplatindosegiventothepatientsinthis
study was the same as in a previous study [21], which deter-
mined a high concentration of oxaliplatin in the patients’
blood. As oxaliplatin was present in the blood of the patients
in the earlier study, the dose was considered representative
for this study, and no positive control was needed.
As t u d yb yG u e r b e te ta l .[ 13] (2007) uses oxaliplatin
in three diﬀerent concentrations (230, 460, and 920mg/L),
which were heated to 41, 43, and 45◦C, during 30, 60, and 90
minutes. The purpose was to determine, by a coupled mass
spectrometry (ICP-MS), if oxaliplatin/Pt vaporised, and as a
result, can be a health hazard to surgeons and theatre staﬀ
during HIPEC. No signiﬁcant quantities of Pt in the air were
detected. Although the present study was comparable to the
study by Guerbert et al. [13], it was more homogeneous, as
dosagesofoxaliplatin,thein-ﬂowtemperatureofoxaliplatin,
and duration of the treatment were the same throughout all
samplings.
A similar study with Mitomycin C [22] analyses samples
of air from the operating room and urine from a surgeon
and a perfusionist during 10 procedures. No detectable levels
of the cytotoxic agent were present in any of the samples.
As the open technique was used, the authors [22]c o n c l u d e
Mitomycin C present in the aerosols is suctioned away
from the surgical ﬁeld during intraoperative chemotherapy
perfusion. This implies that the plastic sheet plays an
important role in the operating room environment.
Occupational exposure of Pt-based cytotoxtic agents in
blood and urine has been investigated. Analyses of Pt in
the blood and urine of pharmacists, and graduate and staﬀ
nurses at three diﬀerent hospitals with various facilities
and routines on how to handle cytotoxic agents, reveals no
increased Pt levels in the blood of pharmacists, but increased
levels in nurses, more so in the staﬀ nurses caring for the
patients [23]. Graduate nurses who handled the drugs were
less exposed. In hospitals with better routines and facilities,
exposure was lower.
Heating the intraperitoneal cytotoxtic agent is important
in treating PC of CRC. The cytotoxic agent in HIPEC is
considered eﬀective and responsible for the destruction of
cancer cells, but hyperthermia might induce cytotoxicity and
apoptosis [24, 25]. Hypertherm chemotherapy appears to
penetrate tumour cells more eﬃciently and decreases vas-
cularity [15]. However, results vary depending on diﬀerent
tumourcells[24].Testsonthecytotoxiceﬀectofhypertherm
oxaliplatin indicate that the potency of the drug intensiﬁes as
it is heated to 41◦C[ 26].
Cytotoxic agents are a risk and there are clear directions
from the Occupational Safety and Health Administration
(OSHA) and the National Institute for Occupational Safety
and Health (NIOSH) on handling and administration [12,
27]. When heating these agents, as in HIPEC, aerosols
are likely to be inhaled by the personnel administering
the treatment [11, 13]. This is the reason HIPEC safety
considerations are documented [11, 14, 28] and should be
followed at all times. The risk of exposure needs to be
determined in order for this treatment to be fully acceptable,
thatistheoutcomeforthepatientagainsttheexposureofthe
treatment staﬀ to the vaporisation of oxaliplatin.
In conclusion, little or no risk of Pt exposure during
HIPEC is apparent when the recommended protective
garments are used and safety considerations are followed.
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